1:1

publication

PROTRIDER is a method for detecting aberrant protein expression from mass spectrometry data that outperforms existing approaches and identifies enrichments of pathogenic variants, supporting its application in rare disease diagnostics and cancer proteomics.

Motivation: Detection of gene regulatory aberrations enhances our ability to interpret the impact of inherited and acquired genetic variation for rare disease diagnostics and tumor characterization. While numerous methods for calling RNA expression outliers from RNA-sequencing data have been proposed, the establishment of protein expression outliers from mass spectrometry data is lacking.

Results: Here, we propose and assess various modeling approaches to call protein expression outliers across three datasets from rare disease
diagnostics and oncology. We use as independent evidence the enrichment for outlier calls in matched RNA-seq samples and the enrichment for rare variants likely disrupting protein expression. We show that controlling for hidden confounders and technical covariates, while simultaneously modeling the occurrence of missing values, is largely beneficial and can be achieved using conditional autoencoders. Moreover, we find that the differences between experimental and fitted log-transformed intensities by such models exhibit heavy tails that are poorly captured with the Gaussian distribution and report stronger statistical calibration when instead using the Student’s t-distribution. Our resulting method, PROTRIDER, outperformed baseline approaches based on raw log-intensities Z-scores, PCA, and isolation-based anomaly detection with Isolation forests. The application of PROTRIDER reveals significant enrichments of AlphaMissense pathogenic variants in protein expression outliers. Overall, PROTRIDER provides a method to confidently identify aberrantly expressed proteins applicable to rare disease diagnostics and cancer proteomics.

Availability and implementation: PROTRIDER is freely available at github.com/gagneurlab/PROTRIDER and also available on Zenodo under
the DOI zenodo.15569781.

Year of publication

2025

Source

Bioinformatics, Volume 41, Issue 12, December 2025

Link to cite

Acces to Link >

Author

Daniela Klaproth-Andrade , Ines F Scheller , Georgios Tsitsiridis , Stefan Loipfinger , Christian Mertes , Dmitrii Smirnov , Holger Prokisch , Vicente A Yépez , Julien Gagneur

You might also be interested in

The RealiseD project launched a new multi-stakeholder survey that invites the rare disease community to share insights and help improve clinical trial enrolment
The two-day event will focus on translating research and policy initiatives into tangible benefits for Rare Disease patients through better prevention, diagnosis, and treatment.
The training responds to the growing need for patient advocates to understand data management, ethical considerations and the role of AI in rare disease research.
13 January – 10 February 2026 | Online webinar series to advance best practices in clinical trial design for rare and ultra rare diseases.